Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinomaReport as inadecuate

Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 16:338

Medical and radiation oncology


BackgroundWe investigated the contribution of subsequent therapy for advanced hepatocellular carcinoma refractory or intolerant to sorafenib. Further, we investigated the impact of sorafenib on overall survival using individual data.

MethodsWe reviewed the medical records of patients with advanced hepatocellular carcinoma treated with sorafenib. Survival after sorafenib treatment and overall survival were defined as the time when we discovered that patients were either refractory or intolerant to sorafenib and the period from the start of sorafenib treatment, respectively, until death during the study. We compared patients’ prognoses according to their subsequent treatment as follows: group A, therapies targeting intrahepatic lesions; group B, systemic therapies alone; group C, no subsequent therapy. We used linear regression analysis to determine whether there was an association with survival after sorafenib treatment and with overall survival.

ResultsOf 79 patients, 63 79.7 % received one or more subsequent therapies 44 and 19 patients in groups A and B, respectively. The five patients who survived more than two years after sorafenib treatment was discontinued responded to therapies targeting intrahepatic lesions. The median survival times of groups A, B, and C were 11.9 months, 5.8 months, and 3.6 months, respectively. Multivariate analysis revealed that group A, Child-Pugh score, serum α-fetoprotein level, and cause of failure of sorafenib treatment were independent prognostic factors for survival after sorafenib treatment. Individual survival after sorafenib treatment correlated highly with overall survival.

ConclusionsTargeting intrahepatic lesions may be useful for treating patients with advanced hepatocellular carcinoma patients after sorafenib treatment is discontinued.

KeywordsHepatocellular carcinoma Sorafenib Subsequent therapy Posttreatment survival Hepatic arterial infusion chemotherapy Electronic supplementary materialThe online version of this article doi:10.1186-s12885-016-2380-4 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Takeshi Terashima - Tatsuya Yamashita - Rika Horii - Kuniaki Arai - Kazunori Kawaguchi - Kazuya Kitamura - Taro Yamashita -

Source: https://link.springer.com/

Related documents